Drug intelligence / Profile preview

BRP-020

Development stage: Preclinical
Lead developer: BoomRay Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BRP-020 is a developmental-stage candidate within the pipeline of Suzhou BoomRay Chuanghe Pharmaceutical (BoomRay). While specific details regarding its molecular target and radionuclide composition have not been publicly disclosed, it is part of BoomRay's focus on Radionuclide Drug Conjugates (RDCs). The company specializes in developing targeted radiopharmaceuticals for oncology, utilizing ligands to deliver diagnostic or therapeutic isotopes (such as Lutetium-177 or Actinium-225) specifically to tumor-associated antigens. BRP-020 likely represents an early-stage research program or a proprietary code for a novel radiotherapeutic or imaging agent intended for the treatment or diagnosis of solid tumors.

Beyond the preview

Go deeper on BRP-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRP-020.

Explore the full profile